Medtronic MDT Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Cardiovascular | $3.8B+9.8% | $3.46B+0.6% | $3.44B+4.6% | $3.29B-1.5% | $3.34B+9.8% | |
| Diabetes | $838M+5.3% | $796M+5.2% | $757M+5.0% | $721M-1.0% | $728M+4.9% | |
| Medical Surgical | $2.39B+9.8% | $2.17B+0.1% | $2.17B+4.2% | $2.08B-5.8% | $2.21B+6.7% | |
| Neuroscience | $2.75B+7.5% | $2.56B-0.2% | $2.56B+6.0% | $2.42B-7.8% | $2.62B+6.6% | |
| Other Operating Segments | $33.75M0.0% | $33.75M0.0% | $33.75M0.0% | $33.75M-1.5% | $34.25M0.0% | |
| Reportable segment operating profit by Business | ||||||
| Cardiovascular | $1.07B+18.8% | $899M+2.5% | $877M+5.9% | $828M-13.3% | $955M+15.3% | |
| Medical Surgical | $605M+21.2% | $499M-6.0% | $531M+7.5% | $494M-14.1% | $575M+12.3% | |
| Neuroscience | $879M+19.3% | $737M-0.4% | $740M+5.0% | $705M-17.8% | $858M+12.6% | |
| Other segment items by Business | ||||||
| Cardiovascular | -$1M+92.9% | -$14M+17.6% | -$17M-13.3% | -$15M-7.1% | -$14M0.0% | |
| Medical Surgical | $5M-16.7% | $6M+200% | $2M+100% | $1M-75.0% | $4M0.0% | |
| Neuroscience | $13M+8.3% | $12M+33.3% | $9M+350% | $2M-83.3% | $12M0.0% | |
| Cost of products sold, excluding amortization of intangible assets by Business | ||||||
| Cardiovascular | $1.27B+9.5% | $1.16B+2.2% | $1.13B+0.2% | $1.13B+0.8% | $1.12B+16.5% | |
| Medical Surgical | $964M+11.2% | $867M+4.3% | $831M+2.1% | $814M-6.4% | $870M+10.4% | |
| Neuroscience | $843M+3.4% | $815M+5.6% | $772M+7.1% | $721M-8.5% | $788M+10.7% | |
| Selling, general, and administrative expense by Business | ||||||
| Cardiovascular | $1.19B+5.2% | $1.13B-1.2% | $1.14B+7.8% | $1.06B+4.7% | $1.01B+0.2% | |
| Medical Surgical | $650M+3.5% | $628M+0.2% | $627M+3.6% | $605M+2.0% | $593M-2.0% | |
| Neuroscience | $875M+4.0% | $841M-3.8% | $874M+5.2% | $831M+2.2% | $813M-0.9% | |
| Currency translation and other by Business | ||||||
| Cardiovascular | $10M+11.1% | $9M— | —— | $28M-68.2% | $88M+310% | |
| Medical Surgical | $110M+104% | $54M— | —— | $203M-72.0% | $725M+307% | |
| Neuroscience | $20M+5.3% | $19M— | —— | $38M-64.2% | $106M+283% | |
| Other Operating Segments | $0— | $0— | $0— | $0-100% | $250K0.0% | |
| Depreciation by Business | ||||||
| Cardiovascular | $67M+1.5% | $66M+17.9% | $56M-12.5% | $64M+10.3% | $58M+3.6% | |
| Medical Surgical | $56M-9.7% | $62M+17.0% | $53M-1.9% | $54M+1.9% | $53M+3.9% | |
| Neuroscience | $85M+6.3% | $80M+1.3% | $79M+2.6% | $77M+6.9% | $72M-1.4% | |
| Research and development expense by Business | ||||||
| Cardiovascular | $273M-3.9% | $284M-5.0% | $299M+6.8% | $280M+8.1% | $259M+4.4% | |
| Medical Surgical | $163M-6.3% | $174M-3.9% | $181M+7.1% | $169M0.0% | $169M+3.0% | |
| Neuroscience | $139M-9.2% | $153M-8.4% | $167M+6.4% | $157M+5.4% | $149M-2.0% | |
| Net Sales by Geography | ||||||
| Ireland | $39M+8.3% | $36M+2.9% | $35M+6.1% | $33M+10.0% | $30M+7.1% | |
| Rest of world | $4.9B+9.2% | $4.49B+1.8% | $4.41B+2.1% | $4.32B-0.7% | $4.35B+8.0% | |
| United States | $4.87B+8.4% | $4.49B-0.5% | $4.52B+6.9% | $4.22B-7.1% | $4.55B+7.3% | |
| Property, plant, and equipment, net by Geography | ||||||
| Ireland | $338M— | —— | —— | —— | $291M— | |
| Rest of world | $1.62B— | —— | —— | —— | $1.41B— | |
| United States | $5.46B— | —— | —— | —— | $5.13B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Medtronic break its business down?
- Medtronic (MDT) reports net sales by business across 6 parts — Cardiovascular, Diabetes, Medical Surgical, Neuroscience and Other operating segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Medtronic's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Medtronic's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
